SDHA related tumorigenesis: a new case series and literature review for variant interpretation and pathogenicity
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Purpose: To evaluate the role of germline SDHA mutation analysis by (1) comprehensive literature review, (2) description of novel germline SDHA mutations and (3) in silico structural prediction analysis of missense substitutions in SDHA. Patients and methods: A systematic literature review and a retrospective review of the molecular and clinical features of patients identified with putative germline variants in UK molecular genetic laboratories was performed. To evaluate the molecular consequences of SDHA missense variants, a novel model of the SDHA/B/C/D complex was generated and the structural effects of missense substitutions identified in the literature, our UK novel cohort and a further 32 “control missense variants” were predicted by the mCSM computational platform. These structural predictions were correlated with the results of tumor studies and other bioinformatic predictions. Results: Literature review revealed reports of 17 different germline SDHA variants in 47 affected individuals from 45 kindreds. A further 10 different variants in 15 previously unreported cases (seven novel variants in eight patients) were added from our UK series. In silico structural prediction studies of 11 candidate missense germline mutations suggested that most (63.7%) would destabilize the SDHA protomer, and that most (78.1%) rare SDHA missense variants present in a control data set (ESP 6500) were also associated with impaired protein stability. Conclusion: The clinical spectrum of SDHA‐associated neoplasia differs from that of germline mutations in other SDH‐subunits. The interpretation of the significance of novel SDHA missense substitutions is challenging. We recommend that multiple investigations (e.g. tumor studies, metabolomic profiling) should be performed to aid classification of rare missense variants before genetic testing results are used to influence clinical management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638 · cited 3×
“…are most frequently identified in SDHB and SDHD (Jafri et al. 2013; Neumann et al. 2004; Gimenez-Roqueplo et al. 2003; Astuti et al. 2001a,b; Baysal et al. 2000), which encode the B and D subunits of the succinate dehydrogenase (SDH) complex (type II mitochondrial complex) which is an…”
BackgroundAstuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087 · cited 3×
“…PCC/PGL, germline mutations are most frequently identified in SDHB and SDHD (Jafri et al. 2013; Neumann et al. 2004; Gimenez-Roqueplo et al. 2003; Astuti et al. 2001a,b; Baysal et al. 2000), which encode the B and D subunits of the succinate dehydrogenase (SDH) complex (type II mitochondrial…”
BackgroundSelf-citationPires, D. E. V., Ascher, D. B., & Blundell, T. L. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku411 · Cited by 932
Self-citationNeumann, H. P. H. (2004) · JAMA · doi:10.1001/jama.292.8.943 · Cited by 893 · cited 9×
“Previously, we and others have found that in silico structural prediction analysis tools can aid the classification of germline SDHB and SDHD variants (Ricketts et al. 2010).”
BackgroundInfluentialMutations in SDHC cause autosomal dominant paraganglioma, type 3
Niemann, S., & Müller, U. (2000) · Nature Genetics · doi:10.1038/81551 · Cited by 875 · cited 1×
“One patient with a sympathetic bladder PGL and a c.91C>T (p.Arg31*) variant (Burnichon et al. 2012), and a second patient with a HNPGL and a c.1534C>T (p.Arg512*) variant (Papathomas et al. 2015).”
BackgroundSDH mutations establish a hypermethylator phenotype in paraganglioma
Letouzé, E., Martinelli, C., Loriot, C., Burnichon, N., Abermil, N., Ottolenghi, C., Janin, M., Menara, M., Nguyen, A. T., Benit, P., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.018 · Cited by 776 · cited 2×
“Similarly, methylome profiling can be used to identify the hypermethylation epigenetic alterations associated with SDHx inactivation (Letouz e et al. 2013).”
BackgroundSDH5 , a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma
Hao, H.-X., Khalimonchuk, O., Schraders, M., Dephoure, N., Bayley, J.-P., Kunst, H., Devilee, P., Cremers, C. W. R. J., Schiffman, J. D., Bentz, B. G., et al. (2009) · Science · doi:10.1126/science.1175689 · Cited by 702 · cited 3×
“PCC/PGL are the most often inherited neuroendocrine tumors with approximately 40% of all cases harboring a genetic mutation in one of at least 13 genes (NF1, RET, VHL, SDHB, SDHC, SDHD, SDHA, SDHAF2, MAX, TMEM127, HIF2A, MDH2) (Yang et al. 2015; Lorenzo et al. 2013; Burnichon et al. 2010; Qin et al. 2010; Hao et al. 2…”
BackgroundGermline mutations in TMEM127 confer susceptibility to pheochromocytoma
Qin, Y., Yao, L., King, E. E., Buddavarapu, K., Lenci, R. E., Chocron, E. S., Lechleiter, J. D., Sass, M., Aronin, N., Schiavi, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.533 · Cited by 379 · cited 3×
“PCC/PGL are the most often inherited neuroendocrine tumors with approximately 40% of all cases harboring a genetic mutation in one of at least 13 genes (NF1, RET, VHL, SDHB, SDHC, SDHD, SDHA, SDHAF2, MAX, TMEM127, HIF2A, MDH2) (Yang et al. 2015; Lorenzo et al. 2013; Burnichon et al. 2010; Qin et al. 2010; Hao et al. 2…”
BackgroundKorpershoek, E., Favier, J., Gaal, J., Burnichon, N., van Gessel, B., Oudijk, L., Badoual, C., Gadessaud, N., Venisse, A., Bayley, J.-P., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1043 · Cited by 277
Cited by
DynaMut: predicting the impact of mutations on protein conformation, flexibility and stability
Rodrigues, C. H., Pires, D. E., & Ascher, D. B. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky300 · Cited by 1,086
Self-citationRodrigues, C. H. M., Pires, D. E. V., & Ascher, D. B. (2021) · Protein Science · doi:10.1002/pro.3942 · Cited by 670
Self-citationSDM: a server for predicting effects of mutations on protein stability
Pandurangan, A. P., Ochoa-Montaño, B., Ascher, D. B., & Blundell, T. L. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx439 · Cited by 497
Self-citationmCSM-NA: predicting the effects of mutations on protein-nucleic acids interactions
Pires, D. E. V., & Ascher, D. B. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx236 · Cited by 127
Self-citationKinact: a computational approach for predicting activating missense mutations in protein kinases
Rodrigues, C. H., Ascher, D. B., & Pires, D. E. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky375 · Cited by 31
Self-citation
Metadata
- Authors
- Casey, R. T., Ascher, D. B., Rattenberry, E., Izatt, L., Andrews, K. A., Simpson, H. L., Challis, B., Park, S., Bulusu, V. R., Lalloo, F., Pires, D. E. V., West, H., Clark, G. R., Smith, P. S., Whitworth, J., Papathomas, T. G., Taniere, P., Savisaar, R., Hurst, L. D., Woodward, E. R., & Maher, E. R.
- Venue
- Molecular Genetics & Genomic Medicine
- Publisher
- Wiley
- Published
- 2017-03-02
- Volume
- 5
- Issue
- 3
- Pages
- 237-250
- ISSN
- 2324-9269 (ISSN-L)
- OpenAlex
- W2594240795
- Cited by
- 51
- References
- 16
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.